APYX MEDICAL CORP (NASDAQ:APYX) Beats Q3 2025 Earnings Estimates

Financial Performance Overview

APYX MEDICAL CORP (NASDAQ:APYX) delivered third-quarter 2025 financial results that notably exceeded analyst expectations on both top and bottom-line metrics. The medical technology company reported revenue of $12.88 million against estimates of $12.24 million, representing a positive surprise of approximately 5.2%. Even more significantly, the company reported a non-GAAP earnings per share of -$0.05, substantially better than the anticipated -$0.10 per share, beating estimates by 50%.

Market Reaction and Recent Performance

The market response to these results has been decisively positive, with the stock showing strong momentum across multiple timeframes:

• Pre-market trading following the earnings release showed a significant surge of approximately 6.7%
• The stock has gained 6.4% over the past week
• Monthly performance stands at 9.4%
• Two-week gains measure 3.6%

This upward trajectory suggests investors are responding favorably to both the earnings beat and the company's strategic developments, particularly the successful commercial launch of new products.

Strategic Developments and Business Highlights

Beyond the financial figures, Apyx Medical achieved several important operational milestones during the quarter. The company initiated the full U.S. commercial launch of its AYON Body Contouring System at the end of the third quarter, with management noting that pre-order demand has exceeded expectations. This new product expansion complements the company's existing Renuvion technology platform and represents a significant growth opportunity in the surgical aesthetics market.

The company maintains its position as a leader in energy-based medical technology, with its Advanced Energy segment focusing on helium plasma technology for both cosmetic surgery and hospital surgical markets. The successful launch execution and stronger-than-expected financial performance indicate effective commercialization of their technology portfolio.

Forward Outlook and Analyst Expectations

Looking ahead, analysts have established expectations for the coming periods that provide context for the company's growth trajectory:

• For the fourth quarter of 2025, analysts project revenue of $17.52 million with an estimated EPS of -$0.06
• Full-year 2025 estimates anticipate revenue of $51 million with an EPS of -$0.37

While the press release did not provide specific forward-looking financial guidance from management, the current analyst estimates suggest expectations for continued revenue growth and progressive improvement in profitability metrics. The company's ability to exceed current quarter estimates while simultaneously launching new products positions it favorably against these projections.

The combination of better-than-expected financial results, successful product launches, and positive market sentiment creates an optimistic backdrop for Apyx Medical as it moves into the final quarter of 2025. Investors will be watching closely to see if the momentum from the AYON launch can drive further upside surprises in the next earnings cycle.

For detailed earnings analysis and updated estimates, visit the APYX earnings and estimates page.

Disclaimer: This article provides financial analysis for informational purposes only and does not constitute investment advice, recommendation, or endorsement of any particular security or investment strategy. Readers should conduct their own research and consult with a qualified financial advisor before making investment decisions.